Clinical trial
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric…
NCT00448916 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00448916 |
|---|---|
| Title | Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures |
| Official title | A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsies, Partial |
| Intervention type | Drug |
| Interventions | Pregabalin |
| Enrollment | 54 |
| Start date | May 1, 2007 |
| Primary completion | Oct 1, 2013 |
| Completion | Oct 1, 2013 |
| First posted | Mar 19, 2007 |
| Last update posted | Jan 25, 2021 |
| Countries | Mexico, South Korea, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: